Read more

December 30, 2021
1 min read
Save

Top in rheumatology: Pediatric fellowships, respiratory tract diseases and RA risk

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

According to data released by the National Resident Matching Program, less than 70% of pediatric rheumatology fellowship programs were filled for the 2022 appointment year.

The data underscore the need to increase interest in pediatric rheumatology as the subspecialty is already experiencing a dire workforce shortage, the American College of Rheumatology said in a press release. It was the top story in rheumatology last week.

ArthritisChild_270388215
Source: Adobe Stock

Another top story was about a study that showed sinusitis, acute respiratory tract burden and pharyngitis may increase the risk for rheumatoid arthritis.

Read these and more top stories in rheumatology below:

Pediatric rheumatology comes up short on Match Day: Just 69% of fellowship slots filled

Results from the 2021 Medical Specialties Matching Program reveal that pediatric rheumatology fellowship programs filled less than 70% of their available slots, according to the American College of Rheumatology. Read more.

Sinusitis, ‘common cold’ may increase risk for developing rheumatoid arthritis

Sinusitis, acute respiratory tract burden and even pharyngitis — also known as the common cold — are potential risk factors for rheumatoid arthritis, according to data published in The Journal of Rheumatology. Read more.

Upadacitinib effective as monotherapy, in combination with non-biologics for PsA

Upadacitinib demonstrates comparable efficacy and safety as monotherapy or in combination with non-biologic disease-modifying antirheumatic drugs in patients with psoriatic arthritis, according to data published in Rheumatology. Read more.

CoherusYusimry nabs FDA approval as seventh Humira biosimilar in cramped market

The FDA has approved the seventh biosimilar to adalimumab, Yusimry (adalimumab-aqvh, Coherus BioSciences), for all eligible indications of the biologic product, the latest in an increasingly crowded biosimilar logjam set to release in 2023. Read more.

Elevated spine symptoms in psoriatic arthritis linked to worse quality of life, disease activity

Patients with self-reported elevated spine symptoms in psoriatic arthritis, with or without a diagnosis of axial disease, had worse quality of life and disease activity overall versus patients without axial manifestations, according to data. Read more.